Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. - Wikidata - awgldk - TriplyDB

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

http://www.wikidata.org/entity/Q35359761

about

Interferon for people with lamivudine-resistant chronic hepatitis B virus infection Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection The role of interferon therapy in hepatitis B Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials A Practical Approach to Management of Chronic Hepatitis B Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors Direct acting antivirals for the treatment of chronic viral hepatitis Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil Treatment of chronic hepatitis.Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.Advancing patient care: integrating new data.The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?Hepatitis B in childhood: An update for the paediatrician Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment Hepatitis B: an important public health issue.Profound suppression of hepatitis B virus replication with lamivudine.Hepatitis B e antigen seroconversion: effects of lamivudine alone or in combination with interferon alpha.Lamivudine for hepatitis B in clinical practice.Management of viral hepatitis B.Doctor-to-patient transmission of viral hepatitis B: is it a problem, is there a solution?Antiviral treatment of chronic hepatitis B virus (HBV) infections Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression.Diagnosis and management of pre-core mutant chronic hepatitis B.Current pharmacotherapy for hepatitis B infection.Treatment of viral hepatitis--2001.Therapeutic management of hepatitis B-related cirrhosis.Evolving therapies for the treatment of chronic hepatitis B virus infection.Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.Chronic hepatitis B: current and future treatment options.One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.Therapy of chronic hepatitis B: current challenges and opportunities.

P2860

Q24185973-BB871C0A-491C-4074-9E42-34690B4E60EC Q24187530-0AFF408C-A7E3-4340-9C0E-0660621F8A7B Q24529082-F131C4C4-C2B2-4911-8CC8-6A00A6F85BBE Q24683341-B49EDB68-20DF-4FCF-94D4-898770A587AE Q24810145-04EAEAFC-2349-4EF1-80E6-7629EDF1F4F9 Q26784241-96835DEE-5D02-4D96-8CCA-007D9424F2A7 Q27016075-F90C5786-DD4C-4498-A867-9FD471F0FF18 Q27020938-B6AB2D63-15B0-4C0A-8215-036875871669 Q27022216-B4A1E582-1154-4846-BE44-6D06E60A8864 Q28203373-7FDC18DF-BE18-4962-8EE4-5D42E9B9E1BC Q28345952-6D86D463-659F-407E-9DAC-74ECD99605EF Q28364240-7B787114-3A19-4A68-8114-871FF3CF5C49 Q30390865-146DE572-33DF-4505-AF3C-3922D7AB0E3C Q30689186-9F779D9F-3F04-40EE-838A-7741013AC08C Q31031231-7C448774-075D-4C80-ADF3-BB1B372E7BB3 Q33365990-45265B96-CA69-49DC-A624-A8E8A5BBC507 Q33574740-AEC7BF54-2047-4B30-A13F-09548EB511B2 Q33588605-22732240-ED60-46BE-9BE9-965ABE7DF5C2 Q33866030-C33A59F7-ADDF-470E-B3FC-0A7724B4C558 Q33867462-7C282B01-C6D3-4FD6-BF14-073FF129846B Q33947147-06773DC3-9D20-4233-BEF1-7EA1E03C0503 Q33947154-3E702547-5A14-47DF-B1D4-B7152F5D32FA Q33947160-EEB74B99-967A-40DA-B84B-79F841B8EB48 Q33947173-E31DBE85-49D2-4A92-8C62-1ACC8A4179EC Q33959006-98E563F3-705E-4DDB-BD2E-B3A8FA0C1D4D Q33962260-0A7BAAA3-1DA3-4ECF-910E-36F2FB7C57F6 Q34223779-C707DA1A-9DA5-4E90-8B39-AB8E8FE82440 Q34299035-EAFD3BCB-DE2B-440F-B04C-625E17EB5D6C Q34365464-11D5F355-8F26-4023-A099-7C78BF315773 Q34368364-AB5FA3EE-E174-4E36-9CA2-7A85E0DCE17D Q34390231-D8C9E0D6-A888-49B1-9143-178D5655E5E1 Q34390398-2D5F43E5-2D98-4969-AA6F-405FA09FA1A0 Q34434784-D0AF654C-4F13-4C10-A0A6-9612EE27BBF5 Q34519117-C3A1C8C3-AB2B-487A-A51F-91A682F028DD Q34584406-E7A0C867-4CD5-4DB5-BCC2-234F043ACF8A Q34594403-DE0D3901-09BF-4051-9724-E2561CB63606 Q34604733-AA0863AF-E368-4C03-8EAD-2A1FF6FB66A1 Q34687438-06981F2A-722A-4462-9545-28AB06145080 Q34928150-6520279B-9660-478D-8E75-94EE4754D4A7 Q34996613-49306D67-176D-4C1E-930F-02338781899B

P2860

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

http://www.wikidata.org/entity/Q35359761

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Lamivudine and alpha interfero ...... infection: a randomised trial.

@ast

Lamivudine and alpha interfero ...... infection: a randomised trial.

@en

type

label

Lamivudine and alpha interfero ...... infection: a randomised trial.

@ast

Lamivudine and alpha interfero ...... infection: a randomised trial.

@en

prefLabel

Lamivudine and alpha interfero ...... infection: a randomised trial.

@ast

Lamivudine and alpha interfero ...... infection: a randomised trial.

@en

P1433

Q35359761-D37CD75F-1EBE-4B77-8672-FC744D5CCF4F

P1476

Q35359761-A2BE98CA-720E-46A5-9FA3-98B375C8E4E8

P2093

Q35359761-2FFD1F17-2ABE-42CC-B6DD-149060FDCB89

Q35359761-40BFFC4C-A0AB-4BB3-87D5-279314E51628

Q35359761-6DF63006-2B67-4D53-87BA-B9CE923EC7A9

Q35359761-7EBA6B98-3B3A-4BC8-B4E2-7B749C6320B5

Q35359761-A9383425-34E1-4842-8321-3A740B919D87

Q35359761-ADE240C2-160C-40B8-8153-D7E0F8B02E49

Q35359761-B225E5B1-470B-4C36-80CF-05E0CD52DA2B

Q35359761-B86A4F59-5B88-40F5-82EE-23485DC9BBEE

Q35359761-D908E822-C330-4E40-B66A-1CFC3EAAAECD

Q35359761-EB9C1F93-16C5-474B-89CE-136775F75D20

P2860

Q35359761-0279DEE7-5F12-4B3D-AC09-1E659098D387

Q35359761-16156E65-A0F7-44A4-83F7-9D58762A78D6

Q35359761-244D925A-08FC-469D-9562-B35A91DCFB19

Q35359761-38BD8682-30BB-4A59-A7B7-71CB65BAF9AF

Q35359761-45BB9578-B3D6-42C0-B775-90957EB150E4

Q35359761-94CC57DD-EF38-4F7E-9684-23F1C2AB0CD0

Q35359761-A7919F9A-D525-4BDD-95E1-F6E4FA43915C

Q35359761-AE4AA7A8-FDAD-4CC2-89D3-64BBC8700A86

Q35359761-C2097F53-D82B-49AF-BCC3-51E537E91890

P304

Q35359761-DF9C298F-78F2-4F64-9D59-7751BB143689

P31

Q35359761-664B48B0-1E15-4C15-A2F7-56E4BC507FF2

P356

Q35359761-A1BC9A31-08C6-4E56-9752-419BBBAD7B70

P407

Q35359761-061F1695-0207-4BC2-8F12-3B667786A474

P433

Q35359761-F1CCDC07-791C-4EB9-A001-C91D8756FFED

P478

Q35359761-5B362FBE-4CB6-4F55-A3FA-827310189549

P577

Q35359761-C8EAC6F1-6F64-4CA9-803E-C83F5DB5E4A2

P5875

Q35359761-DE424C62-A7BE-48BE-B964-01A96F69F814

P698

Q35359761-650A4D31-E2B5-443E-8234-B61DF1568E4F

P932

Q35359761-E41F1895-F2A6-4B64-A4EB-0316E77CFCF0

P356

P1433

P1476

Lamivudine and alpha interfero ...... infection: a randomised trial.

@en

P2093

A Dhillon

http://www.w3.org/2001/XMLSchema#string

A Moorat

http://www.w3.org/2001/XMLSchema#string

B Willems

http://www.w3.org/2001/XMLSchema#string

D F Gray

http://www.w3.org/2001/XMLSchema#string

G Farrell

http://www.w3.org/2001/XMLSchema#string

J Barber

http://www.w3.org/2001/XMLSchema#string

J Cianciara

http://www.w3.org/2001/XMLSchema#string

J Heathcote

http://www.w3.org/2001/XMLSchema#string

M Sherman

http://www.w3.org/2001/XMLSchema#string

S W Schalm

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

Side effects of alpha interferon.

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors.

Histological improvement after anti-viral treatment for chronic hepatitis B virus infection.

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

P304

562-568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.46.4.562

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2000-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276943399

http://www.w3.org/2001/XMLSchema#string

P698

10716688

http://www.w3.org/2001/XMLSchema#string

P932

1727894

http://www.w3.org/2001/XMLSchema#string